Clinical Trial Update: Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing long-term immunogenicity of a bivalent norovirus VLP vaccine (NoV Vaccine) in adults; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers
• Norovirus Infection Disease

Drugs mentioned

• NoV Vaccine

Snippet

Sponsor: Takeda | Conditions: Healthy Volunteers, Norovirus | Phase 2 | Status: COMPLETED | Results posted: 2022-10-06